KalVista Pharmaceuticals, Inc. KALV 深 滬
等待開盤 08-21 09:30:00 美东时间
12.91
+0.100
+0.78%
華盛通- 最 高12.98
- 今 開12.81
- 成交量 57.72万股
- 最 低 12.30
- 昨 收 12.81
- 總市值 6.45亿
- 52周最高 16.32
- 市盈率 靜 --
- 換手率 1.16%
- 52周最低 7.30
- 委 比 52.84%
- 總股本 4995.37万
- 歷史最高 45.00
- 量 比 0.72
- 振 幅 5.31%
- 歷史最低 4.12
- 每 手 1
- 風險率 1.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
Metagenomi, a precision genetic medicines company, has appointed Laurence Reid, PhD, to its Board of Directors. With 30 years of experience in biotech, Dr. Reid brings expertise in company building, R&D strategy, and organizational growth. His加入将助力Metagenomi advance its gene editing technologies and deliver curative genetic medicines for patients. The company leverages AI and machine learning to develop next-generation genome editing therapies ta...
08-11 20:05
KalVista Pharmaceuticals Maintains EU Orphan Designation For Sebetralstat, Securing Potential 10 Years Of Market Exclusivity Upon Approval
Sebetralstat is one of only two hereditary angioedema therapies to maintain orphan designation, underscoring its major contribution to patient careIf approved, sebetralstat will be granted 10 years of market exclusivity
08-11 19:16
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista Pharmaceuticals (NASDAQ:KALV), Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their produ...
07-25 21:23
KalVista gets UK nod for Ekterly
KalVista Pharmaceuticals (NASDAQ:KALV) said that the UK health regulator has granted marketing authorization for Ekterly (sebetralstat), a plasma inhibitor, to treat hereditary angioedema attacks in p...
07-16 04:44
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
07-14 20:14
国投证券-生物医药行业新药周观点：创新药5月进院数据更新，多个新纳入医保创新药快速进院中-250713
（转自：研报虎） 本周新药行情回顾： 2025年7月7日-2025年7月13日，新药板块涨幅前5企业：北海康成(114.5%)、前沿生物(41.4%)、君...
07-13 21:23
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $27 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $27 price target.
07-11 18:19
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update
KalVista Pharmaceuticals, Inc. ( ($KALV) ) has released its Q4 earnings. Here i...
07-11 11:53
KalVista Pharma Q4 EPS $(0.99) Misses $(0.82) Estimate
KalVista Pharma (NASDAQ:KALV) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.82) by 20.58 percent. This is a 2.94 percent increase over losses of $(1.02) per share from
07-10 20:23
KalVista Pharmaceuticals GAAP EPS of -$3.69
KalVista Pharmaceuticals press release (NASDAQ:KALV): FY GAAP EPS of -$3.69. $220.6M in cash, providing runway into 2027 More on KalVista Pharmaceuticals KalVista: FDA Approval Of EKTERLY As Oral On-D...
07-10 19:01
